Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations
BMJ 2022; 378 doi: https://doi.org/10.1136/bmj-2021-068956 (Published 31 August 2022) Cite this as: BMJ 2022;378:e068956
- Joseph E Maakaron, assistant professor of medicine,
- Marie Hu, assistant professor of medicine,
- Najla El Jurdi, assistant professor of medicine
- Correspondence to: maaka001{at}umn.edu
Abstract
Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during the past five years, boasting impressive response rates and durable remissions for patients who previously had no viable options. In this review, we provide a brief historical overview of their development. We focus on the practical aspects of a patient’s journey through this treatment and the unique toxicities and current best practices to manage those. We then discuss the key registration trials that have led to approvals for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma (MCL), and multiple myeloma. Finally, we consider the future development and research directions of this cutting edge therapy.
Footnotes
Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors
Contributors: JEM, MH, and NEJ prepared and reviewed the manuscript, and approved the final version.
Patient involvement: No patients were directly involved in the creation of this article.
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: none.
Provenance and peer review: Commissioned; externally peer reviewed.
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.